Philina Lee
CIK 1845080 · Chief Commercial Officer · last filed 2025-07-21
Philina Lee is a Chief Commercial Officer who has filed 15 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for BPMC, was dated Jul 21, 2025. Across all open-market trades the lifetime net is −$5.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
15
-$5.31M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) Delisted | Chief Commercial Officer | 0 | $129.46 | $0 | -$5.31M | 10 | 2025-07-21 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −41,996 | $0 | EDGAR |
| 2025-03-07 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −3,733 | -$331.5K | EDGAR |
| 2025-03-04 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2024-08-07 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$1.08M | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-03-15 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −6,276 | -$702.3K | EDGAR |
| 2024-03-11 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −2,934 | -$266.1K | EDGAR |
| 2024-03-06 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
| 2024-02-14 | Blueprint Medicines Corp (BPMC) Delisted | Exer (M) | +261 | $488 | EDGAR |
| 2023-06-14 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |